These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 21029218

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
    Blank PR, Moch H, Szucs TD, Schwenkglenks M.
    Clin Cancer Res; 2011 Oct 01; 17(19):6338-46. PubMed ID: 21807639
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L.
    Magy Onkol; 2010 Dec 01; 54(4):383-94. PubMed ID: 21163770
    [Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples.
    Bozzetti C, Negri FV, Azzoni C, Naldi N, Nizzoli R, Bortesi B, Zobbi V, Bottarelli L, Tiseo M, Silini EM, Ardizzoni A.
    Diagn Cytopathol; 2013 Jul 01; 41(7):595-8. PubMed ID: 22833420
    [Abstract] [Full Text] [Related]

  • 10. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
    Ling Y, Ying JM, Qiu T, Shan L, Guo L, Lü N.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep 01; 41(9):590-4. PubMed ID: 23157825
    [Abstract] [Full Text] [Related]

  • 11. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.
    J Clin Oncol; 2009 Dec 10; 27(35):5924-30. PubMed ID: 19884556
    [Abstract] [Full Text] [Related]

  • 12. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A.
    Cancer Treat Rev; 2009 May 10; 35(3):262-71. PubMed ID: 19117687
    [Abstract] [Full Text] [Related]

  • 13. [BRAF gene mutation in wild-type KRAS patients with colorectal cancers].
    Roa I, Game A, Bizama C, Schalper K.
    Rev Med Chil; 2014 Jan 10; 142(1):55-60. PubMed ID: 24861115
    [Abstract] [Full Text] [Related]

  • 14. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.
    Br J Cancer; 2010 Mar 30; 102(7):1137-44. PubMed ID: 20234366
    [Abstract] [Full Text] [Related]

  • 15. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 16. Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
    Lu W, Wei H, Li M, Wang H, Liu L, Zhang Q, Liu L, Lu S.
    Mol Med Rep; 2015 Jul 20; 12(1):1219-24. PubMed ID: 25815786
    [Abstract] [Full Text] [Related]

  • 17. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P.
    Cancer Cytopathol; 2013 Sep 20; 121(9):500-7. PubMed ID: 23495083
    [Abstract] [Full Text] [Related]

  • 18. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J, Sun ZW, Li YY, Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep 20; 41(9):579-83. PubMed ID: 23157823
    [Abstract] [Full Text] [Related]

  • 19. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.
    Eur J Cancer; 2010 Jul 20; 46(11):1997-2009. PubMed ID: 20413299
    [Abstract] [Full Text] [Related]

  • 20. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y.
    Oncol Rep; 2014 May 20; 31(5):2115-22. PubMed ID: 24626880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.